{"id":"NCT04456673","sponsor":"Sanofi","briefTitle":"Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate to Severe COPD With Type 2 Inflammation","officialTitle":"A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety, and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) With Type 2 Inflammation","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2020-07-06","primaryCompletion":"2024-02-28","completion":"2024-05-27","firstPosted":"2020-07-02","resultsPosted":"2025-03-17","lastUpdate":"2025-05-29"},"enrollment":935,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Chronic Obstructive Pulmonary Disease"],"interventions":[{"type":"DRUG","name":"Dupilumab SAR231893","otherNames":["Dupixent"]},{"type":"DRUG","name":"Inhaled Corticosteroid","otherNames":[]},{"type":"DRUG","name":"Inhaled Long-Acting Beta Agonist","otherNames":[]},{"type":"DRUG","name":"Inhaled Long-Acting Muscarinic Antagonist","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Dupilumab","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"Primary Objective:\n\nTo evaluate the efficacy of dupilumab administered every 2 weeks in patients with moderate or severe Chronic Obstructive Pulmonary Disease (COPD) as measured by\n\n* Annualized rate of acute moderate or severe COPD exacerbation (AECOPD)\n\nSecondary Objectives:\n\nTo evaluate the effect of dupilumab administered every 2 weeks on\n\n* Pre-bronchodilator forced expiratory volume in 1 second (FEV1) over 12 weeks compared to placebo\n* Health related quality of life, assessed by the change from baseline to Week 52 in the St. George's Respiratory Questionnaire (SGRQ)\n* Pre-bronchodilator FEV1 over 52 weeks compared to placebo\n* Lung function assessments\n* Moderate and severe COPD exacerbations\n* To evaluate safety and tolerability\n* To evaluate dupilumab systemic exposure and incidence of antidrug antibodies (ADA)","primaryOutcome":{"measure":"Annualized Rate of Moderate or Severe Chronic Obstructive Pulmonary Disease (COPD) Exacerbations Over the 52-week Treatment Period","timeFrame":"Baseline (Day 1) to Week 52","effectByArm":[{"arm":"Placebo","deltaMin":1.295,"sd":null},{"arm":"Dupilumab 300 mg q2w","deltaMin":0.859,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0002"}]},"eligibility":{"minAge":"40 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":10},"locations":{"siteCount":334,"countries":["United States","Argentina","Australia","Belgium","Brazil","Bulgaria","Canada","Chile","Colombia","Czechia","France","Germany","Greece","Hungary","Latvia","Lithuania","Mexico","Netherlands","Peru","Poland","Portugal","Romania","Russia","Serbia","Slovakia","South Africa","Spain","Ukraine","United Kingdom"]},"refs":{"pmids":["39894389","38767614"],"seeAlso":["https://sanofi.trialsummaries.com/Study/StudyDetails?id=25232&tenant=MT_SNY_9011"]},"adverseEventsSummary":{"seriousAny":{"events":79,"n":464},"commonTop":["Covid-19","Headache","Accidental Overdose","Nasopharyngitis"]}}